What is the effectiveness and safety of treatment of the co-morbid condition of asthma with medications known to improve asthma outcomes in individuals without SCD?
Considering the fact that Blacks bear a disproportionate degree of asthma morbidity and mortality, should treatment recommendations be different for Blacks vs. Caucasians?
Study patient-provider communication of asthma self-management requirements to see where gaps in communication may contribute to suboptimal self-management decisions. Examine patients’ decision-making in the home management of asymptomatic and acute. Compare different approaches to the delivery of asthma self-management education and best practices for supporting the patient as they gain competency in this area.
Systematically examine the contribution of unconventional beliefs and negative attitudes to inadequate clinical outcomes for asthma.
Budesonide/fomoterol controller/reliever therapy ('smart' therapy) in large US studies - adults
Prospective studies on acetaminophen and asthma - randomized/controlled/adequately powered - use in pregnancy and asthma development in utero, use in early childhood
Adequately powered randomized vitD trials - as primary prevention, and after asthma diagnosis
Bronchial thermoplasty in oral steroid-dependent (high dose certainly >10 mg/day) asthmatics
ICS/LABA/tiotropium fixed triple-combination inhaler therapy
Are there biomarkers or phenotypic characteristics that will allow us to identify the patients with asthma who will experience a more rapid decline in lung function?
What factors predict exacerbations in asthma and can they be prevented?
What options for therapy for severe asthma are available for the non-eosinophilic phenotype?
What are the features of airway remodeling about which we consistently agree and in whom are they most likely to occur?